Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Oncternal Goes Public Via Reverse Merger With GTx

Executive Summary

All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.

Advertisement

Related Content

Mehta Analysis: BMS/Celgene Merger Shows Big Pharma Is Stuck In Wrong Groove
Shionogi Builds Digital Therapeutics Presence Through Akili Alliance
Pro Vs. Con: A Side-By-Side Look At Investor Concerns, Bristol's Defenses Of Celgene Deal
Numab's Pipeline To Benefit From Intarcia Licensing Its ND016
Celgene/Bristol: Happy Union Or Runaway Bride?
Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies
Pharma Showing More Interest In Conditional Approvals; Back On EU Expert Group Agenda
Trial investigators busted for insider trading on 'halted' GTx studies
GTx Muscle Wasting Drug Fails, But Data Offer Possible New Path

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124890

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel